Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19 EUR | -0.03% | -7.27% | +13.88% |
12:02am | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |
Jun. 07 | GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk | RE |
Chart: Technical Analysis
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- GSK Stock
- GS71 Stock
- Charts GSK plc